Skip to main
OSTX

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies is positioned for success, with a strong focus on addressing the unmet need for treatments in osteosarcoma and other solid tumors, as highlighted by their innovative pipeline and mission-driven approach. The company has robust clinical and regulatory momentum, with upcoming meetings and expected initiation of a confirmatory Phase 3 trial. Additionally, multiple regulatory designations and potential for a priority review voucher provide a strong foundation for expedited development and future financial opportunities.

Bears say

OS Therapies is facing significant regulatory challenges with its Phase 3 launch in 2026, as the company must align with multiple agencies and conduct a global confirmatory trial for its potential cancer treatment. This timeline may result in delays and higher costs, further impacting the company's financial stability. Additionally, OS Therapies is currently in the preclinical stages for its other product candidate, OST-tADC, and has not yet generated any revenues, making it a risky investment.

OSTX has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 2 analysts, OSTX has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.